Genetically engineered swine influenza virus and uses thereof

US8124101B2 · kind B2 · utility

Assignees

• Mount Sinai School of Medicine · US
• St. Jude Children's Research Hospital, Inc. · US
• The United States of America, as represented by the Secretary of Agriculture · US

Inventors

• Peter Palese · Leonia, US
• Adolfo Garcia-Sastre · New York, US
• Richard J. Webby · Memphis, US
• Juergen A. Richt · Ames, US
• Robert G. Webster · Memphis, US
• Kelly M. Lager · Nevada, US

Key dates

• Filing date: Jun 1, 2005
• Grant date: Feb 28, 2012
• Expiry date: Jul 27, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/16171
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.